fludarabine has been researched along with Vascular Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Björklund, A; Garming-Legert, K; Hassan, M; Ljungman, P; Mattsson, J; Remberger, M; Serafi, IE; Sundin, M; Törlen, J | 1 |
| Andreesen, R; Blüml, S; Burger, V; Eissner, G; Haffner, S; Holler, E; Iacobelli, M | 1 |
| Fujiwara, M; Hashimoto, S; Koike, T; Satoh, N; Takenouchi, S | 1 |
3 other study(ies) available for fludarabine and Vascular Diseases
| Article | Year |
|---|---|
Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cystitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infant; Male; Middle Aged; Transplantation Conditioning; Vascular Diseases; Vidarabine | 2017 |
Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity.
Topics: Antineoplastic Agents; Cell Line; Cell Movement; Endothelial Cells; Endothelium, Vascular; Oligodeoxyribonucleotides; Polydeoxyribonucleotides; Transplantation Conditioning; Vascular Diseases; Vidarabine | 2005 |
Switching of donor cells after urgent second cord blood transplantation for suspected graft failure.
Topics: Adult; Anti-Inflammatory Agents; Bone Marrow; Cord Blood Stem Cell Transplantation; Delayed Graft Function; Donor Selection; Female; Ferritins; Graft Survival; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Macrophages; Methylprednisolone; Myeloablative Agonists; Tissue Donors; Transplantation Conditioning; Vascular Diseases; Vidarabine | 2007 |